Chairpersons :

Shishir Shetty, S. D. Banavali, Anil Sanganeria

Reviewer :

Sandeep Goyle

1. Overall survival results from the randomized phase II study of Palbociclib (P) in combination with Letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) Author: Finn RS Citation: J Clin Oncol. 2017;34(suppl; abstr 1001)

2. PALOMA-3: Phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in asian patients Author: Hiroji Iwata Citation: JGO – Journal of Global Oncology, 289 Volume 3, Issue 4, August 2017